Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

731
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
731
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

762
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
762
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

702
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
702
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.5K
The pathophysiology of pneumonia involves the following steps:
2.5K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Start, Stop & Select: The Steward's Hat Trick.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Electronic Clinical Quality Measures of Antibiotic Use in Hospitalized Adults with Uncomplicated Community-acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Comparing the Antimicrobial Resistance Crisis to the Coronavirus Disease 2019 Pandemic: A Randomized Public Health Messaging Experiment.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Outcomes associated with empiric azithromycin use among patients hospitalized with non-severe community-acquired pneumonia: emulation of a target trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Another Point Goes to Team Short Course: Implications of the BALANCE Trial Post-Hoc Analysis for Pseudomonas aeruginosa Bloodstream Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Streamlining antibiotic use in community acquired pneumonia: A quality improvement initiative.

Journal of hospital medicine·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Sepsis Diagnostic Excellence and its Association with Mortality in Adults with Potential Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

10-Year Trends in Attributable and Contributable Mortality of Culture-Positive Invasive Aspergillosis in Patients with Hematologic Malignancies: Have We Reached the "Ceiling Efficacy Effect" of Modern Antifungals?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines.

Leila S Hojat1, Maryrose R Laguio-Vila2, Liam R Sullivan3

  • 1Department of Internal Medicine, Division of Infectious Disease, Emory University, Atlanta, Georgia, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|December 4, 2025
PubMed
Summary
This summary is machine-generated.

The 2025 community-acquired pneumonia (CAP) guideline

Keywords:
dissentinterdisciplinary communicationpneumoniapractice guidelines

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

51.8K

Related Experiment Videos

Last Updated: Jan 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

51.8K

Area of Science:

  • Infectious Diseases
  • Clinical Practice Guidelines
  • Respiratory Medicine

Background:

  • Clinical practice guidelines significantly impact patient care.
  • The 2025 community-acquired pneumonia (CAP) guideline update by the American Thoracic Society (ATS) recommended antibacterials for viral CAP.
  • Transparency and rigor in guideline development are crucial.

Purpose of the Study:

  • To evaluate the data supporting antibacterial use in viral CAP.
  • To analyze the development process of the 2025 CAP guideline.
  • To provide recommendations for future infectious diseases guideline development.

Main Methods:

  • Review of the 2025 ATS CAP guideline recommendations.
  • Analysis of the evidence base for treating viral CAP with antibacterials.
  • Reflection on the guideline development process, including logistics and methodology.

Main Results:

  • Lack of supporting data for prescribing antibacterials for viral CAP.
  • Identified shortcomings in the guideline development process.
  • The Infectious Diseases Society of America (IDSA) withdrew co-sponsorship due to concerns.

Conclusions:

  • The 2025 CAP guideline recommendation for antibacterials in viral CAP is not supported by current evidence.
  • Improvements in guideline development processes are needed for transparency, communication, and methodology.
  • Adherence to antimicrobial stewardship and the "first do no harm" principle is paramount.